UCLA-Led Study Finds New Pancreatic Cancer Drug ‘Significantly Extended Survival’

Royce Hall on the campus of University of California–Los Angeles (UCLA) in Los Angeles, Calif., on June 22, 2025. Joyce Kuo/The Epoch Times

LOS ANGELES—An international study co-led by UCLA found that an investigational targeted therapy significantly extended survival for pancreatic cancer patients, researchers said on May 31.

The study found that patients who received the drug daraxonrasib lived a median of 13.2 months compared with 6.7 months for those who received investigator’s choice chemotherapy.